Tandem Diabetes Care(TNDM) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, Tandem achieved over $1 billion in worldwide sales, marking a 12% growth year-over-year, with U.S. sales increasing by 10% to $707 million and international sales growing by 15% to $308 million [17][19] - Q4 2025 saw record worldwide sales of $290 million, representing a 15% year-over-year growth, with U.S. Q4 sales increasing by 14% to $210 million [17][18] - Gross margin expanded by 3 percentage points to 54% for the full year, with the highest quarterly margin ever recorded at 58% [19][20] - Adjusted EBITDA was 11% of sales in Q4, a 10 percentage point improvement over the prior year, and the company reported its first positive operating margin since 2021 at 3% of sales in Q4 [20][21] Business Line Data and Key Metrics Changes - The U.S. market saw more than 27,000 pump shipments in Q4, with renewals from loyal customers making up over half of the shipments [18] - Internationally, Q4 sales grew 17% year-over-year, delivering $80 million in sales and 11,000 pump shipments [19] - Sales through the pharmacy channel nearly doubled from Q3, growing to $16 million or 7% of total U.S. sales in Q4 [18] Market Data and Key Metrics Changes - The company began direct commercial operations in the UK, Switzerland, and Austria, with plans to expand further in 2026 and 2027 [9][27] - Direct sales represented approximately 5% of total international sales in 2025, expected to increase to about 15% in 2026 [28] Company Strategy and Development Direction - Tandem's strategy focuses on modernizing commercial operations, delivering new technology, and reshaping the business model to drive sustainable growth and profitability [8][13] - The company is transitioning to a pay-as-you-go reimbursement model, which is expected to enhance customer adoption and create a more predictable revenue stream [22][25] - New product launches planned for 2026 include Mobi Tubeless, which will be the first patch pump offering with extended wear technology [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term objectives of accelerated sales growth, with a gross margin target of at least 65% and an operating margin of 25% [21] - The transition to a pay-as-you-go model is anticipated to moderate sales growth in 2026 but is expected to drive significant long-term value creation [23][30] - Management highlighted the importance of pump shipments as a key indicator of market expansion and growth [29] Other Important Information - The company exited 2025 with nearly $300 million in total cash and investments, generating free cash flow in both Q3 and Q4 [20] - The anticipated revenue headwinds from the pay-as-you-go model are expected to be most pronounced in 2026, with a projected sales range of $730 million to $745 million [26][30] Q&A Session Summary Question: Can you provide context on the expected growth rates for U.S. and international shipments? - Management indicated that overall revenue growth is expected to be in the line of 10-11%, with double-digit growth in shipments and a return to growth in new shipments [36] Question: What is the current status of pharmacy coverage and contracting? - Management stated that contracts with major PBMs cover about 80% of lives, with formulary access currently at roughly one-third of lives covered [41] Question: Why is now the right time for the pay-as-you-go model? - Management emphasized that the experience gained in Q4 and positive conversations with payers made this the right time for the transition [45] Question: How will the transition to direct sales impact revenue? - Management noted that while there will be headwinds in the short term, the long-term benefits of direct sales and pricing premiums will be significant [78] Question: What are the expected impacts of the new product launches on growth? - Management expressed confidence that new technology and improved sales organization will drive growth, with Mobi and other products expected to contribute positively [64]